Welcome to our dedicated page for Mediwound SEC filings (Ticker: MDWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MediWound Ltd. (MDWD) SEC filings page brings together the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. MediWound files reports on Form 6-K to furnish press releases, financial statements, and transaction details, and uses shelf registration statements on Form F-3 and employee share plans on Form S-8 for capital markets activities. These documents provide structured insight into the company’s biotechnology business focused on enzymatic, non-surgical therapies for tissue repair.
In its Form 6-K filings, MediWound furnishes quarterly and interim financial results, including condensed consolidated statements of financial position and profit or loss, along with management press releases discussing revenue, operating loss, cash balances, and non-IFRS measures such as Adjusted EBITDA. Other 6-Ks describe registered direct offerings of ordinary shares under an effective Form F-3 shelf registration statement, including purchase agreements, use of proceeds for EscharEx® pre-commercial activities and manufacturing expansion, and related legal opinions.
Filings also reference government-supported programs and contracts that are important to MediWound’s burn and chronic wound portfolio. BARDA- and U.S. Department of Defense-funded projects for NexoBrid®, including clinical development, regulatory submissions, emergency procurement, and formulation work, are discussed in the company’s press releases that are incorporated by reference into SEC reports. Insider share purchases by senior leadership are reported on Form 6-K, providing transparency into management’s trading activity.
On Stock Titan, these SEC filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain key points from lengthy filings, highlight changes in financial condition, and surface important details about offerings, grants, and clinical or manufacturing milestones. Users can quickly locate quarterly updates, registration statements, and reports that reference NexoBrid and EscharEx, and review how MediWound describes its risks, funding, and strategic priorities over time.
MediWound Ltd. reported the results of an extraordinary general meeting of shareholders. As of the January 16, 2026 record date, there were 12,815,094 ordinary shares outstanding and entitled to vote. Shareholders holding 3,844,528 ordinary shares, about 30% of the outstanding shares, were present in person or by proxy, satisfying the quorum requirements under the company’s Articles of Association and Israeli Companies Law.
The single proposal presented at the meeting was approved by the requisite majority under the Israeli Companies Law, excluding abstentions. The final vote count showed 3,490,863 votes in favor (90.9%), 350,902 votes against (9.1%), and 2,763 abstentions. The 6-K and its exhibits are incorporated by reference into MediWound’s existing Form S-8 and Form F-3 registration statements.
T. Rowe Price Associates, Inc. filed an amended Schedule 13G/A reporting its beneficial ownership of 554,498 shares of MediWound Ltd. common stock, representing 4.3% of the class as of the event date. The firm has sole voting power over 535,181 shares and sole dispositive power over 554,498 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MediWound. T. Rowe Price Associates also affirms that the filing should not be construed as an admission that it is the beneficial owner of these securities.
HOLD Alapkezelo Zrt., a Hungarian investment fund management company, filed an amended ownership report showing a significant stake in MediWound Ltd. common shares.
The firm is deemed to beneficially own 1,039,954 common shares, representing approximately 8.1% of MediWound’s outstanding common stock, based on 12,835,186 shares outstanding as of January 16, 2026. HOLD Alapkezelo Zrt. has sole voting and sole dispositive power over all of these shares and no shared voting or dispositive power.
The filer certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of MediWound, and are not held in connection with any control-related transaction.
MediWound Ltd. reported ownership by a Rosalind-affiliated group in a Schedule 13G/A. Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon together report beneficial ownership of 912,319 MediWound common shares, or 7% of the class, based on 12,835,186 shares outstanding as of January 16, 2026.
The filing explains that this figure includes 163,265 shares issuable upon exercise of warrants that are subject to a 9.99% ownership blocker. Excluding those blocked warrants, Rosalind Master Fund may be deemed to beneficially own 749,054 shares, or about 5.84% of the common stock. The group states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of MediWound.
MediWound Ltd. investor Yelin Lapidot group reports a 5.95% passive stake in the company’s ordinary shares. Amendment No. 1 to Schedule 13G shows Yelin Lapidot Holdings Management Ltd., together with Dov Yelin and Yair Lapidot, beneficially owning 763,069 ordinary shares with shared voting and dispositive power.
The stake is held through mutual and provident funds managed by wholly owned subsidiaries of Yelin Lapidot Holdings, for the benefit of fund members. The reporting persons expressly state the securities were not acquired and are not held to change or influence control of MediWound.
MediWound Ltd. has called an extraordinary general meeting for February 19, 2026 to ask shareholders to approve an increase of 300,000 ordinary shares reserved for issuance under its 2024 Share Incentive Plan. The record date for voting is the close of business on January 16, 2026, when 12,835,186 ordinary shares were issued and outstanding, with each share entitled to one vote.
The Board and compensation committee say the additional shares are needed to continue granting equity awards to employees, officers, directors and other service providers, since only about 132,996 unallocated shares remain available under the plan. If approved, the total equity incentive pool across the 2014 and 2024 plans would cover 1,724,819 shares on a fully diluted base of 16,826,464 shares, representing 10.25% potential dilution. The Board unanimously recommends voting “FOR” the proposal and plans to register the new 300,000-share pool on an additional Form S-8 after approval.
MediWound Ltd. filed a Form 6-K presenting a corporate update and multi‑year financial outlook ahead of the J.P. Morgan Healthcare Conference. The company reports approximately
The update highlights clinical and operational milestones. An interim assessment and enrollment completion for the Phase III EscharEx® VALUE trial in venous leg ulcers are expected by year‑end 2026, with planned expansion into diabetic foot and pressure ulcers during 2026. MediWound also reports that its expanded NexoBrid® manufacturing facility is fully operational, with regulatory approvals targeted for 2026. The revenue expectations and cash figures are described as preliminary, unaudited, and subject to change after year‑end 2025 audit procedures.
MediWound Ltd. submitted a Form 6-K to furnish a press release titled “MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update.” The filing notes that the full press release is attached as Exhibit 99.1 and contains the detailed financial and corporate information for the third quarter of 2025.
The company also states that the information in this Form 6-K, including Exhibit 99.1 but excluding quotes from senior management, is incorporated by reference into multiple existing registration statements on Form S-8 and Form F-3. This allows the attached information to be used in connection with those previously filed securities registration documents.
MediWound Ltd. (MDWD): Schedule 13D/A Amendment No. 6 filed by Access Industries affiliates, Clal entities, and Len Blavatnik updates ownership details. The group reports beneficial ownership of 1,481,521 Ordinary Shares, representing 11.56% of the class, based on 12,821,433 shares outstanding as of September 30, 2025.
Most reporting persons list shared voting and dispositive power over 1,481,521 shares. Clal Life Sciences L.P. directly owns 1,172,710 shares (9.15%) with sole voting and dispositive power. Clal Biotechnology Industries Ltd. directly owns 308,811 shares and may be deemed to share voting and investment power over the 1,172,710 shares held by Clal Life Sciences L.P. The amendment revises Items 5(a) and 5(b); the date of event is September 30, 2025.
MediWound Ltd. submitted a Form 6-K reporting corporate disclosures and attachments. The filing lists the company's principal executive office address in Yavne, Israel, and indicates the company files annual reports on Form 20-F. The exhibits include a legal opinion from Meitar | Law Offices and Exhibit 10.1, a Form of Securities Purchase Agreement dated